The article " Unstoppable Yields: 3 Blue-Chip Stocks to Maximize Returns " first appeared on MarketBeat.

With the recent rise of diseases, pharmaceutical companies are pushing boundaries in medicine, from life-saving treatments to ...

Pfizer’s efforts will span small molecule ... for breast cancer – and the BREAKWATER study of BRAF inhibitor Braftovi (encorafenib) as first-line therapy for BRAF-mutated metastatic colorectal ...

According to Report Ocean, the US Urinary Tract Infection (UTI) Therapeutics market is anticipated to grow at a CAGR of ~$% between 2022-2028 owing to rise in cases of UTIs, technological advancements ...

Two-drug therapy with Braftovi and Erbitux also performed well ... The BEACON data is also welcome news for Pfizer, which just agreed to buy Array in an $11.4 billion deal due to complete later ...

A new study found that fewer African and Asian patients had clinically actionable alterations for lung, breast, and colorectal cancer.

Court revives lawsuit against Pfizer's diversity fellowship Group claims Pfizer program discriminates against white, Asian-American applicants Pfizer defends diversity efforts, lawsuit follows ...

AUSTIN (KXAN) — Texas Attorney General Ken Paxton filed a notice of appeal on Wednesday to continue his lawsuit against Pfizer Inc., for its alleged “unlawful misrepresentations concerning the ...

(Bloomberg) -- GSK Plc and Pfizer Inc.’s vaccines for a common respiratory virus must carry warnings that they may be tied to an increased risk of a rare neurological side effect that can lead ...